The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.

Basson M, Ntais D, Ayyub R, Wright D, Lowin J, Chartier F, Roze S, Norrbacka K

Diabetes therapy : research, treatment and education of diabetes and related disorders13 Nov 2017Cited by 9 (Europe PMC)

PMID29134607PMCIDPMC5801216DOI10.1007/s13300-017-0321-0PepBankPUB-29134607

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a French T2DM simulation, dulaglutide had lower lifetime costs than exenatide QW (€41,562 vs €43,021).
In plain wordsA computer model predicted lower lifetime costs with dulaglutide than exenatide QW for T2DM in France.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLifetime costs
Study
n: not reported in source
QuintilesIMS CORE Diabetes Model
Comparator
Exenatide QW
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Lifetime costs
41,562 EUR
dulaglutide
Lifetime costs
43,021 EUR
exenatide QW
Source sentences
Summary
Dulaglutide 1.5 mg was associated with lower costs (lifetime costs €41,562 vs €43,021) and increased health benefits (lifetime quality-adjusted life years: QALYs 9.804 vs 9.757) versus exenatide QW for the treatment of T2DM in France.
2 context sentences(design, population, supporting numbers)
Summary · context
The QuintilesIMS CORE Diabetes Model was used to estimate the expected lifetime direct medical costs and outcomes of T2DM from the perspective of the French National Health Service.
Summary · context
In the absence of head-to-head data, relative efficacy was derived from a network meta-analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2913460701
02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In a French T2DM simulation, exenatide QW had higher lifetime costs than dulaglutide (€43,021 vs €41,562).
In plain wordsA computer model predicted higher lifetime costs with exenatide QW than dulaglutide for T2DM in France.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLifetime costs
Study
n: not reported in source
QuintilesIMS CORE Diabetes Model
Comparator
Dulaglutide
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
Dulaglutide 1.5 mg was associated with lower costs (lifetime costs €41,562 vs €43,021) and increased health benefits (lifetime quality-adjusted life years: QALYs 9.804 vs 9.757) versus exenatide QW for the treatment of T2DM in France.
2 context sentences(design, population, supporting numbers)
Summary · context
The QuintilesIMS CORE Diabetes Model was used to estimate the expected lifetime direct medical costs and outcomes of T2DM from the perspective of the French National Health Service.
Summary · context
In the absence of head-to-head data, relative efficacy was derived from a network meta-analysis.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2913460702
03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a French T2DM simulation, dulaglutide produced more lifetime QALYs than exenatide QW (9.804 vs 9.757).
In plain wordsA computer model predicted more years adjusted for quality of life with dulaglutide than exenatide QW in French T2DM.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLifetime quality-adjusted life years
Study
n: not reported in source
QuintilesIMS CORE Diabetes Model
Comparator
Exenatide QW
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Lifetime QALYs
9.804 QALYs
dulaglutide
Lifetime QALYs
9.757 QALYs
exenatide QW
Source sentences
Summary
Dulaglutide 1.5 mg was associated with lower costs (lifetime costs €41,562 vs €43,021) and increased health benefits (lifetime quality-adjusted life years: QALYs 9.804 vs 9.757) versus exenatide QW for the treatment of T2DM in France.
2 context sentences(design, population, supporting numbers)
Summary · context
The QuintilesIMS CORE Diabetes Model was used to estimate the expected lifetime direct medical costs and outcomes of T2DM from the perspective of the French National Health Service.
Summary · context
In the absence of head-to-head data, relative efficacy was derived from a network meta-analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2913460703
04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In a French T2DM simulation, exenatide QW produced fewer lifetime QALYs than dulaglutide (9.757 vs 9.804).
In plain wordsA computer model predicted fewer years adjusted for quality of life with exenatide QW than dulaglutide in French T2DM.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLifetime quality-adjusted life years
Study
n: not reported in source
QuintilesIMS CORE Diabetes Model
Comparator
Dulaglutide
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
Dulaglutide 1.5 mg was associated with lower costs (lifetime costs €41,562 vs €43,021) and increased health benefits (lifetime quality-adjusted life years: QALYs 9.804 vs 9.757) versus exenatide QW for the treatment of T2DM in France.
2 context sentences(design, population, supporting numbers)
Summary · context
The QuintilesIMS CORE Diabetes Model was used to estimate the expected lifetime direct medical costs and outcomes of T2DM from the perspective of the French National Health Service.
Summary · context
In the absence of head-to-head data, relative efficacy was derived from a network meta-analysis.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2913460704
05Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a French T2DM simulation, dulaglutide had a 99.5% cost-effectiveness probability at a willingness to pay of €30,000 versus exenatide QW.
In plain wordsA computer model predicted a 99.5% probability that dulaglutide was cost-effective versus exenatide QW at the specified payment threshold.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableCost-effectiveness probability
Study
n: not reported in source
QuintilesIMS CORE Diabetes Model
Comparator
Exenatide QW
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
The CEAC indicated a 99.5% probability that dulaglutide would be considered cost-effective at a willingness to pay of €30,000.
2 context sentences(design, population, supporting numbers)
Summary · context
The QuintilesIMS CORE Diabetes Model was used to estimate the expected lifetime direct medical costs and outcomes of T2DM from the perspective of the French National Health Service.
Summary · context
In the absence of head-to-head data, relative efficacy was derived from a network meta-analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2913460705
06Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a French T2DM simulation comparing dulaglutide with exenatide QW, sensitivity analyses indicated robust results across plausible inputs.
In plain wordsThe French T2DM model comparison of dulaglutide and exenatide QW remained robust when plausible inputs changed.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSensitivity analysis robustness
Study
n: not reported in source
QuintilesIMS CORE Diabetes Model
Comparator
Exenatide QW
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
OWSA and PSA indicated that results were robust across a range of plausible input parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
The QuintilesIMS CORE Diabetes Model was used to estimate the expected lifetime direct medical costs and outcomes of T2DM from the perspective of the French National Health Service.
Summary · context
In the absence of head-to-head data, relative efficacy was derived from a network meta-analysis.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2913460706
07Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In a French T2DM simulation comparing exenatide QW with dulaglutide, sensitivity analyses indicated robust results across plausible inputs.
In plain wordsThe French T2DM model comparison of exenatide QW and dulaglutide remained robust when plausible inputs changed.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSensitivity analysis robustness
Study
n: not reported in source
QuintilesIMS CORE Diabetes Model
Comparator
Dulaglutide
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
OWSA and PSA indicated that results were robust across a range of plausible input parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
The QuintilesIMS CORE Diabetes Model was used to estimate the expected lifetime direct medical costs and outcomes of T2DM from the perspective of the French National Health Service.
Summary · context
In the absence of head-to-head data, relative efficacy was derived from a network meta-analysis.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2913460707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.

Summary

Results from this study7

Studies that did not test the peptide alone7

Version history

Subjects

Publication types

Keywords